scholarly journals EE8 BRIDGING HEALTH TECHNOLOGY ASSESSMENT WITH MULTICRITERIA DECISION ANALYSIS (MCDA) AND AN ETHICAL FRAMEWORK FOR COMPLEX DECISIONS: CASE STUDY OF GROWTH HORMONE FOR TURNER SYNDROME

2009 ◽  
Vol 12 (7) ◽  
pp. A230
Author(s):  
MM Goetghebeur ◽  
M Wagner ◽  
H Khoury ◽  
D Rindress ◽  
JP Grégoire ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Decision Analysis ◽  
Health Technology Assessment ◽  
Turner Syndrome ◽  
Technology Assessment ◽  
Health Technology ◽  
Multicriteria Decision Analysis ◽  
Ethical Framework ◽  
Multicriteria Decision

scholarly journals Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward

2019 ◽  
Vol 22 (11) ◽  
pp. 1283-1288 ◽  
Author(s):  
Rob Baltussen ◽  
Kevin Marsh ◽  
Praveen Thokala ◽  
Vakaramoko Diaby ◽  
Hector Castro ◽  
...  
Keyword(s):  
Decision Analysis ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Multicriteria Decision Analysis ◽  
Multicriteria Decision ◽  
The Way

scholarly journals Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis

2020 ◽  
Vol 40 (6) ◽  
pp. 830-845
Author(s):  
Aris Angelis ◽  
Mark Thursz ◽  
Vlad Ratziu ◽  
Alastair O’Brien ◽  
Lawrence Serfaty ◽  
...  
Keyword(s):  
Drug Development ◽  
Decision Analysis ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Nonalcoholic Steatohepatitis ◽  
Health Technology ◽  
Value Theory ◽  
Multicriteria Decision Analysis ◽  
Multicriteria Decision ◽  
Value Preferences

Background. The assessment of value along the clinical development of new biopharmaceutical compounds is a challenging task. Complex and uncertain evidence has to be analyzed, considering a multitude of value preferences from different stakeholders. Objective. To investigate the use of multicriteria decision analysis (MCDA) to support decision making during drug development while considering payer and health technology assessment (HTA) value concerns, by applying the Advance Value Framework in nonalcoholic steatohepatitis (NASH) and testing for the consistency of the results. Design. A multiattribute value theory methodology was applied and 2 rounds of decision conferences (DCs) were organized in 3 countries (England, France, and Germany), with the participation of national key experts and stakeholders using the MACBETH questioning protocol and algorithm. A total of 51 health care professionals, patient advocates, and methodologists, including (ex-) committee members or assessors from national HTA bodies, participated in 6 DCs in the study countries. Target Population. NASH patients in fibrosis stages F2 to 3 were considered. Interventions. The value of a hypothetical product profile was assessed against 3 compounds under development using their phase 2 results. Outcome Measures. DC participants’ value preferences were elicited involving criteria selection, options scoring, and criteria weighting. Results. Highly consistent valuation rankings were observed in all DCs, always favoring the same compound. Highly consistent rankings of criteria clusters were observed, favoring therapeutic benefit criteria, followed by safety profile and innovation level criteria. Limitations. There was a lack of comparative treatment effects, early evidence on surrogate endpoints was used, and stakeholder representativeness was limited in some DCs. Conclusions. The use of MCDA is promising in supporting early HTA, illustrating high consistency in results across countries and between study rounds.

scholarly journals Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden

2018 ◽  
Vol 3 (2) ◽  
pp. 238146831879621 ◽  
Author(s):  
Aris Angelis
Keyword(s):  
Prostate Cancer ◽  
Decision Analysis ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Value Theory ◽  
Multiple Criteria ◽  
Decision Makers ◽  
Multiple Criteria Decision Analysis

Background. Multiple criteria decision analysis (MCDA) has been identified as a prospective methodology for assisting decision makers in evaluating the benefits of new medicines in health technology assessment (HTA); however, limited empirical evidence exists from real-world applications. Objective. To test in practice a recently developed MCDA methodological framework for HTA, the Advance Value Framework, in a proof-of-concept case study with decision makers. Methods. A multi-attribute value theory methodology was adopted applying the MACBETH questioning protocol through a facilitated decision-analysis modelling approach as part of a decision conference with four experts. Settings. The remit of the Swedish Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket [TLV]) was adopted but in addition supplementary value dimensions were considered. Patients. Metastatic castrate-resistant prostate cancer patients were considered having received prior chemotherapy. Interventions. Abiraterone, cabazitaxel, and enzalutamide were evaluated as third-line treatments. Measurements. Participants’ value preferences were elicited involving criteria selection, options scoring, criteria weighting, and their aggregation. Results. Eight criteria attributes were finally included in the model relating to therapeutic impact, safety profile, socioeconomic impact, and innovation level with relative importance weights 44.5%, 33.3%, 14.8%, and 7.4% per cluster, respectively. Enzalutamide scored the highest overall weighted preference value score, followed by abiraterone and cabazitaxel. Dividing treatments’ overall weighted preference value scores by their costs derived “costs per unit of value” for ranking the treatments based on value-for-money grounds. Limitations. Study limitations included lack of comparative clinical effects across treatments and the small sample of participants. Conclusion. The Advance Value Framework has the prospects of facilitating the evaluation process in HTA and health care decision making; additional research is recommended to address technical challenges and optimize the use of MCDA for policy making.

Sign in / Sign up

Export Citation Format

Share Document